Skip to main content
SpringerLink
Log in

Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The efficacy and safety of direct oral anticoagulants is well established in patients with atrial fibrillation. However, data on their use in the oldest old patients (≥ 85 years), who have the highest risk of bleeding, is scarce. Objective The aim of this study was to evaluate the safety of direct oral anticoagulants in the oldest old patients with atrial fibrillation and assess the impact of age on major bleeding events. Setting Anticoagulation Clinic of the Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia. Methods From our single-centre prospective registry we enrolled 2260 consecutive atrial fibrillation patients aged ≥ 65 years that were started on dabigatran, rivaroxaban or apixaban. The mean duration of treatment exposure was 735 days. The primary outcome was the incidence of major bleeding. The incidence of thromboembolic events and death were also assessed. Potential risk factors for major bleeding were evaluated using Cox regression analysis. Main outcome measure Rate of major bleeding. Results During the follow-up 106 patients experienced major bleeding (2.3%/year). The oldest old patients (≥ 85 years) had the highest risk of any major bleeding (HR 2.50, 95% CI 1.44–4.32, p = 0.001), intracranial bleeding (HR 4.74, 95% CI 1.48–15.14, p < 0.01) and major gastrointestinal bleeding (HR 2.32, 95% CI 1.10–4.89, p < 0.03) compared to the group of patients aged 65–74 years, even though the majority of them were treated with reduced doses of direct oral anticoagulants. Significant predictors for major bleeding were age group ≥ 85 years (HR 2.52, 95% CI 1.43–4.47, p = 0.001) and history of bleeding (HR 3.32, 95% CI 1.87–5.90, p < 0.001). The incidence of a composite of stroke, transient ischemic attack and systemic embolism was 1.3%/year. Conclusion In this prospective real-world clinical study we have shown that the oldest old patients have the highest risk of major bleeding, which is further increased with a patient’s history of bleeding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. 1991;22(8):983–8.

    Article  CAS  PubMed  Google Scholar 

  2. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited. Stroke. 2013;44(11):3103–8.

    Article  PubMed  Google Scholar 

  3. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Saposnik G, Black SE, Hakim A, Fang J, Tu JV, Kapral MK. Age disparities in stroke quality of care and delivery of health services. Stroke. 2009;40(10):3328–35.

    Article  PubMed  Google Scholar 

  5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.

    Article  PubMed  Google Scholar 

  6. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J-P, Berge E, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–14.

    Article  PubMed  Google Scholar 

  7. Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark. Sci Rep. 2016;6(1):31477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation. 2011;123(21):2363–72.

    Article  CAS  PubMed  Google Scholar 

  9. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism. Circulation. 2014;130(2):138–46.

    Article  CAS  PubMed  Google Scholar 

  10. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the Aristotle trial. Eur Heart J. 2014;35(28):1864–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, et al. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine. JAMA Cardiol. 2016;1(6):673–81.

    Article  PubMed  Google Scholar 

  12. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54(8):1231–6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mant J, Hobbs FR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.

    Article  CAS  PubMed  Google Scholar 

  14. Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015–23.

    Article  CAS  PubMed  Google Scholar 

  15. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.

    Article  CAS  PubMed  Google Scholar 

  16. R Core Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. https://www.R-project.org. Accessed 12 Mar 2020

  17. Nishida T, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al. Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF registry. Heart Vessels. 2019;34(12):2021–30.

    Article  PubMed  Google Scholar 

  18. Monelli M, Molteni M, Cassetti G, Bagnara L, De Grazia V, Zingale L, et al. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study—data from the registry of patients on non-vitamin K oral anticoagulants (Regina). Vasc Health Risk Manag. 2019;15:19–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Poli D, Antonucci E, Ageno W, Bertù L, Migliaccio L, Martinese L, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: results from the prospective multicenter START2-REGISTER study. PLoS ONE. 2019;14(5):e0216831.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Russo V, Attena E, Di Maio M, Mazzone C, Carbone A, Parisi V, et al. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. J Thromb Thrombolysis. 2019. https://doi.org/10.1007/s11239-019-01923-9.

    Article  PubMed  Google Scholar 

  21. Lai CL, Chen HM, Liao MT, Lin TT. Dabigatran, rivaroxaban, and warfarin in the oldest adults with atrial fibrillation in taiwan. J Am Geriatr Soc. 2018;66(8):1567–74.

    Article  PubMed  Google Scholar 

  22. Šinigoj P, Malmström RE, Vene N, Rönquist-Nii Y, Božič-Mijovski M, Pohanka A, et al. Dabigatran concentration: variability and potential bleeding prediction in ‘real-life’ patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2015;117(5):323–9.

    Article  PubMed  Google Scholar 

  23. Miklič M, Mavri A, Vene N, Söderblom L, Božič-Mijovski M, Pohanka A, et al. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol. 2019;75(8):1069–75.

    Article  PubMed  Google Scholar 

  24. Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Net clinical benefit of non-vitamin K antagonist versus vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019;132(6):749–57.e5.

    Article  CAS  PubMed  Google Scholar 

  25. Giustozzi M, Vedovati MC, Verso M, Scrucca L, Conti S, Verdecchia P, et al. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: a multicentre observational study. Int J Cardiol. 2019;281:56–61.

    Article  PubMed  Google Scholar 

  26. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation. 2018;138(1):37–47.

    Article  PubMed  Google Scholar 

  27. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–64.

    Article  CAS  PubMed  Google Scholar 

  28. De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and Other thromboembolic events in atrial fibrillation trial. Am Heart J. 2016;175:175–83.

    Article  PubMed  Google Scholar 

  29. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events. J Am Coll Cardiol. 2014;63(9):891–900.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the physicians involved in “Trombo” registry: G. Tratar, T. Vižintin-Cuderman, M. Gubenšek, and M. Miklič.

Funding

The study was supported by the Slovenian Research Agency (Grant No. P3-0308).

Author information

Authors and Affiliations

  1. Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Petra Šinigoj, Nina Vene & Alenka Mavri

  2. Department of Agronomy, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia

    Katarina Košmelj

Authors
  1. Petra Šinigoj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nina Vene
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katarina Košmelj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alenka Mavri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petra Šinigoj.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Šinigoj, P., Vene, N., Košmelj, K. et al. Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience. Int J Clin Pharm 42, 445–452 (2020). https://doi.org/10.1007/s11096-020-01008-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-020-01008-1

Keywords

Search

Navigation